References

Abdelaziz. (2022). AAO Eye Wiki.

Aiello, L. P., Pierce, E. A., Foley, E. D., Takagi, H., Ogata, N., Lindsey, P. S., ... & King, G. L. (1994). Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. New England Journal of Medicine, 331(22), 1480-1487.

Amirikia, A., Scott, I. U.,  Murray, T. G.,  Goff, M. J.,  Malkin, D. D.,  Forrester, J. V. (2001).Circumferential Retinal Scatter Photocoagulation as a Predictive Factor for Visual Loss in Central Retinal Vein Occlusion. Ophthalmology, 108(2), 372-377

American Society of Retina Specialists (ASRS). (n.d.). Branch Retinal Vein Occlusion. Retrieved from [https://www.asrs.org/patients/retinal-diseases/24/branch-retinal-vein-occlusion](https://www.asrs.org/patients/retinal-diseases/24/branch-retinal-vein-occlusion)

Atchison, E. A., Wood, K. M., Mattox, C. G., Barry, C. N., Lum, F., & MacCumber, M. W. (2018). The Real-World Effect of Intravitreous Anti-Vascular Endothelial Growth Factor Drugs on Intraocular Pressure: An Analysis Using the IRIS Registry. Ophthalmology, 125(5), 676-682.

Brolucizumab (Beovu) PI. Novartis. (2022).

Brown, D. M., Campochiaro, P. A., Singh, R. P., Li, Z., Gray, S., Saroj, N., ... & Haller, J. A. (2010). Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology, 117(6), 1124-1133.e1.

Campochiaro, P. A. (2013). Molecular pathogenesis of retinal and choroidal vascular diseases. Journal of Molecular Medicine, 91, 311–321.

Campochiaro, P. A., Brown, D. M., Awh, C. C., Lee, S. Y., Gray, S., Saroj, N., ... & Rubio, R. G. (2010). Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology, 117(6), 1102-1112.e1.

Ciulla, T., Pollack, J. S., & Williams, D. F. (2021). Visual acuity outcomes and anti-VEGF therapy intensity in macular oedema due to retinal vein occlusion: a real-world analysis of 15 613 patient eyes. British Journal of Ophthalmology, 105(12), 1696-1704.

Central Vein Occlusion Study Group. (1984). Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology, 98, 271–278.

Central Vein Occlusion Study Group M. (1995). A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion: The Central Vein Occlusion Study Group M report. Ophthalmology, 102, 1425–1433.

Dev, S., & Buckley, R. J. (1999). Nd: YAG laser hyaloidotomy for premacular hemorrhage. Ophthalmic Surgery and Lasers, 30(3), 181-187.

Do, D. V., Nguyen, Q. D., Boyer, D., Schmidt-Erfurth, U., Varma, R., Heier, J. S., ... & Sandbrink, R. (2020). One-Year Outcomes of the Phase 3 PIONEER Study of Brolucizumab in Diabetic Macular Edema. Retina, 40(4), 643-647.

EyeWiki. (n.d.). Central Retinal Vein Occlusion. Retrieved from [https://eyewiki.org/Central_Retinal_Vein_Occlusion](https://eyewiki.org/Central_Retinal_Vein_Occlusion)

Faricimab (Vabysmo) PI. (2023). Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO).

Fauser, S., Muether, P. S., Lobo, C., Hillenkamp, J., & спонсорирано, M. (2014). Photodynamic therapy in retinal vein occlusion: a systematic review and meta-analysis. American Journal of Ophthalmology, 158(3), 532-536.

Ferrara, N., Adamis, A. P. (2016). Ten years of anti-VEGF therapy. Nature Reviews Drug Discovery, 15, 385–403.

Flaxel, C. J., Adelman, R. A., Bailey, S. T., Fawzi, A. A., Lim, J. I., Flaxel, C. J., ... & Williams, G. A. (2020). Retinal Vein and Artery Occlusions Preferred Practice Pattern®. Ophthalmology, 127, P288-P320.

Gale, R., Mahmood, S., Eckert, C., Fraser, C., Talks, S., Stratton, I., ... & Gardner, I. D. (2021). Visual acuity after treatment for macular oedema secondary to retinal vein occlusion in the UK: a real-world study. British Journal of Ophthalmology, 105(4), 549-554.

Gaudreault, J., Gunde, T., Floyd, H. S., Arias-Carrion, O., Kurihara, T., Geisen, P., ... & Yang, X. (2012). Preclinical Pharmacology and Safety of Anti-VEGF Single-Chain Antibody Fragment RTH258 for Neovascular AMD. Investigative Ophthalmology & Visual Science, 53(10), 3025.

Genentech. (2022, October 26). Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO).

Haller, J. A., Bandello, F., Belfort, R., Jr, Blumenkranz, M. S., Cunha de Souza, E., Figuera, J., ... & Brown, D. M. (2010). Randomized controlled trial of an intravitreous dexamethasone implant in patients with macular edema due to retinal vein occlusion. Ophthalmology, 117(6), 1134-1146.

Hayreh, S. S. (2011). Retinal vein occlusion. Ophthalmology, 118(10), 1927-1928.

Hayreh, S. S. (2013). Prevalent misconceptions about ischemic retinal disorders. JAMA Ophthalmology, 131(6), 799-807.

Holz, F. G., Brittain, C., Chopdar, A., Ebneter, A., García-Layana, M.,... & Simader, C. (2016). Predictive　Factors　for　Response　to　Anti-VEGF　Agents　in　Neovascular　AMD. Ophthalmology, 123(5), 1080-1089.

Hsu, M. Y., Yu, Y. S., Chen, C. H., Chen, H. C., Liu, C. H., Hsu, W. M., & Chang, C. J. (2016). Aqueous humor levels of pigment epithelium-derived factor and vascular endothelial growth factor in retinal vein occlusion. Scientific Reports, 6, 34631.

Huang, H., Ding, Y., & Jiang, X. (2010). Vascular endothelial growth factor as a target for cancer therapy. Nature Reviews Cancer, 10, 575–585.

Ip, M. S., Scott, I. U., VanVeldhuisen, P. C., Oden, N. L., Blodi, B. A., Fisher, A. J., ... & Central Retinal Vein Occlusion Study Group. (2009). A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Archives of Ophthalmology, 127(9), 1101-1114.

Kanda, A., Nakanishi, Y., Uemura, A., Yamashita, H., Ishikawa, K., Tsujikawa, A., ... & Yoshimura, N. (2015). Vitreous levels of inflammatory cytokines are associated with macular edema type in branch retinal vein occlusion. Scientific Reports, 5, 17946.

Klaassen, I., Van Noorden, C. J., Schlingemann, R. O., & Van Hinsbergh, V. W. (2013). Molecular basis of blood–retinal barrier breakdown and therapeutic approaches. Progress in Retinal and Eye Research, 34, 19–48.

Kolar, P. (2014). Central and branch retinal vein occlusion: current diagnostic and therapeutic strategies. Journal of Ophthalmology.

Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012 Oct;154(4):682-686.e2. doi: 10.1016/j.ajo.2012.03.047. Epub 2012 Jul 19. PMID: 22818800.

Krohne TU, Eter N, Holz FG, Meyer CH. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008 Oct;146(4):508-12. doi: 10.1016/j.ajo.2008.05.036. Epub 2008 Jul 17. PMID: 18635152.

Lashay, A., Riazi-Esfahani, M., Nikoonahad, H., & Asgari, S. (2019). Macular Vein Occlusion: a Review. Journal of Ophthalmic & Vision Research, 14(3), 336-366.

Lattanzio, R., et al. (2011). Vascular endothelial growth factor and retinal vein occlusion: an update. Ophthalmologica, 225(3), 135–143.

Laouri, M.,  Allemeier, C. A.,  Good, M. S.,  McLaughlin, M. M.,  Ness, S. A.,  Varma, R., & Friedman, D. S. (2011).Patterns of use and predictors of switching among the three available anti-vascular endothelial growth factor agents for treatment of neovascular age-related macular degeneration. Eye, 25(11), 1426-1434.

McAllister, I. L., Constable, I. J., Graham, G. A., & Fitzmaurice, E. W. (1995). Laser-induced chorioretinal venous anastomosis for treatment of central retinal vein occlusion: a preliminary report. Archives of Ophthalmology, 113(4), 456-462.

Miyamoto, K., Khosrof, S., Bursell, S. E., Rohan, R., Murata, T., Clermont, A. C., ... & Aiello, L. P. (2000). Prevention of leukostasis and retinal vascular dysfunction in streptozotocin-induced diabetic rats by intercellular adhesion molecule-1 antibody. American Journal of Pathology, 156(5), 1733-1739.

Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013 Nov;156(5):989-993.e2. doi: 10.1016/j.ajo.2013.06.020. Epub 2013 Aug 12. PMID: 23938122.

Nicholson, L., et al. (2017). Predictors of visual acuity outcomes in retinal vein occlusion treated with anti-VEGF therapy. American Journal of Ophthalmology, 182, 118–125.

O'Mahoney, P. R., Wong, D. T., & Ray, J. G. (2008). Retinal vein occlusion and the risk of subsequent cardiovascular disease events: a systematic review and meta-analysis. Archives of Ophthalmology, 126(5), 692-699.

Ozkok, A., et al. (2018). Evaluation of Choroidal Thickness in Branch Retinal Vein Occlusion. Ophthalmic Retina, 2(6), 582-586.

Regula JT et al. EMBO Mol Med. 2016;8(11):1265-1288, with erratum in Regula JT et al. EMBO Mol Med. 2019;11(5):e10666.

Rehak, M., & Wiedemann, P. (2010). Central retinal vein occlusion: From bench to bedside.Journal of Thrombosis and Haemostasis, 8(9), 1886-1894.

Retina Today. (2018, April). RVO Overview. Retrieved from [https://retinatoday.com/articles/2018-apr/rvo-overview](https://retinatoday.com/articles/2018-apr/rvo-overview)

Romano, M. R., et al. (2023). Retinal vein occlusion: From pathophysiology to treatment. Asia-Pacific Journal of Ophthalmology, 12(2), 196-210.

Sivaprasad, S., Amoaku, W. M., & Hykin, P. G. (2016). Management of retinal vein occlusion: current evidence and emerging therapies. Eye, 30(4), 591-611.

The Central Vein Occlusion Study Group. (1993). Baseline and early natural history report. The Central Vein Occlusion Study. Archives of Ophthalmology, 111(8), 1087-1095.

Tsui, I., et al. (2011). A comparison of OCT retinal thickness parameters after intravitreal bevacizumab for central retinal vein occlusion and branch retinal vein occlusion. Retina, 31(6), 1053-1059.

Wang, B., et al. (2022). Research Progress on Risk Factors, Pathogenesis, and Treatment of Retinal Vein Occlusion. Frontiers in Pharmacology, 13, 859951.